Tumor onset was greatly accelerated in Lck-Dlx5;Lck-MyrAkt2 transgenic mice, with median survival being only 8 weeks versus 24 weeks in Lck-MyrAkt2 mice and 39 weeks in Lck-Dlx5 mice (Fig. 1A). Here, LCK is linked to neoplasm.